Amphetamine Use Disorder
Find comprehensive information on Amphetamine Use Disorder (Stimulant Use Disorder, Methamphetamine Use Disorder) diagnosis, including clinical documentation, medical coding, and healthcare resources. Learn about diagnostic criteria, treatment options, and best practices for accurate record-keeping related to amphetamine and stimulant addiction. This resource is designed for healthcare professionals seeking guidance on proper coding and documentation for Amphetamine Use Disorder.
Problematic amphetamine use leading to significant impairment or distress.
Increased heart rate, elevated blood pressure, agitation, paranoia, weight loss, tooth decay.
Outpatient treatment, inpatient detox, residential rehab, support groups.
ICD-10 Code Families
Complete code families applicable to F15.20
When to use each related code
| Description | When to use |
|---|---|
| Problematic amphetamine use leading to impairment. | Use for addiction to amphetamines, like speed or Adderall. Consider stimulant use disorder if specific amphetamine not known. |
| Problematic stimulant use, including cocaine, not just amphetamines. | Use when stimulant addiction present but specific substance (e.g., amphetamine, cocaine) is unknown or mixed. |
| Problematic methamphetamine use leading to impairment. | Use specifically for addiction to methamphetamine (crystal meth, ice). |
Best-practice checklist
- ✓Amphetamine use, frequency, amount, duration
- ✓Document impairment: social, occupational, physical
- ✓Withdrawal symptoms, cravings, failed quit attempts
- ✓Specify amphetamine type: methamphetamine, dextroamphetamine
- ✓ICD-10 F15.20, DSM-5 criteria, SUD, stimulant
Common pitfalls to avoid
Coding requires specifying the type of amphetamine (e.g., methamphetamine, dextroamphetamine) for accurate billing and data analysis. Unspecified type leads to data integrity issues.
Confusing substance use disorder with amphetamine-induced disorders (e.g., psychosis, anxiety) can lead to inaccurate coding and clinical documentation improvement (CDI) queries.
Lack of documentation specifying the severity (mild, moderate, severe) and course specifiers (in early remission, in sustained remission) impacts reimbursement and quality reporting.
Best-practice tips
- 01ICD-10 F15.10, detailed HPI: amphetamine type, frequency, route
- 02Document cravings, withdrawal (ICD-10 F15.20), impact on function
- 03Assess comorbidities (anxiety, depression): code accurately
- 04Therapy, support groups: document treatment plan, response to therapy
- 05Medication management if indicated: justify, document efficacy
Step-by-step checklist
- 1
1. 2+ amphetamine use criteria (DSM-5/ICD-10) documented?
- 2
2. Assess for intoxication/withdrawal symptoms.
- 3
3. Screen for co-occurring mental health disorders.
- 4
4. Document impact on social/occupational function.
Ready-to-paste narrative
Patient presents with features consistent with Amphetamine Use Disorder (Stimulant Use Disorder, Methamphetamine Use Disorder). The patient reports a maladaptive pattern of amphetamine use leading to clinically significant impairment or distress, as manifested by meeting at least two of the following DSM-5 criteria within a 12-month period: amphetamine taken in larger amounts or over a longer period than intended; persistent desire or unsuccessful efforts to cut down or control amphetamine use; a great deal of time spent in activities necessary to obtain, use, or recover from the effects of amphetamine; craving, or a strong desire or urge to use amphetamine; recurrent amphetamine use resulting in a failure to fulfill major role obligations at work, school, or home; continued amphetamine use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of amphetamine; important social, occupational, or recreational activities are given up or reduced because of amphetamine use; recurrent amphetamine use in situations in which it is physically hazardous; amphetamine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by amphetamine; tolerance, as defined by either a need for markedly increased amounts of amphetamine to achieve intoxication or desired effect or a markedly diminished effect with continued use of the same amount of amphetamine; withdrawal, as manifested by either the characteristic amphetamine withdrawal syndrome or amphetamine (or a closely related substance, like a stimulant) is taken to relieve or avoid withdrawal symptoms. Differential diagnoses considered include other substance use disorders, mood disorders, and anxiety disorders. Treatment plan includes psychosocial interventions such as cognitive behavioral therapy (CBT) and motivational interviewing, contingency management, and consideration for pharmacotherapy options. Patient education provided regarding addiction treatment, relapse prevention, and community resources. Follow-up appointment scheduled to monitor progress and adjust treatment plan as needed. ICD-10 code F15.10 for Amphetamine Use Disorder will be utilized for billing and coding purposes. Prognosis guarded given the chronic nature of addiction.
Common questions and answers
What are the most effective evidence-based interventions for stimulant use disorder, specifically methamphetamine and amphetamine, in a primary care setting?+
Addressing stimulant use disorder, including methamphetamine and amphetamine misuse, in primary care requires a multi-faceted approach rooted in evidence-based interventions. Contingency management, utilizing motivational incentives, has demonstrated efficacy in promoting abstinence. Cognitive behavioral therapy (CBT) equips patients with coping mechanisms to manage cravings and triggers. Medication-assisted treatment (MAT), while limited for stimulants, can include bupropion for methamphetamine dependence to reduce cravings and withdrawal symptoms. Integrating these interventions with harm reduction strategies, such as safe injection practices and overdose education including naloxone distribution, is crucial. Explore how combining behavioral therapies like CBT with contingency management can improve patient outcomes in primary care. Consider implementing routine screening for stimulant use disorder using validated tools to facilitate early intervention.
How can I differentiate between amphetamine-induced psychosis and primary psychotic disorders like schizophrenia when assessing a patient presenting with psychotic symptoms?+
Differentiating between amphetamine-induced psychosis and primary psychotic disorders like schizophrenia requires careful clinical assessment. While overlapping symptoms exist, several key features can aid in the distinction. Amphetamine-induced psychosis often presents with prominent visual and tactile hallucinations, paranoia, and agitation, with symptoms typically resolving within days to weeks of stimulant cessation. In contrast, schizophrenia often involves a broader range of symptoms, including negative symptoms like flat affect and avolition, as well as a longer duration of illness with persistent or episodic symptoms even without stimulant use. A thorough history, including substance use patterns and family history of psychotic disorders, is essential. Consider implementing validated screening tools for substance use and psychosis. Learn more about the diagnostic criteria for primary psychotic disorders to enhance differential diagnosis and ensure appropriate treatment planning.
What are the best practices for managing amphetamine withdrawal symptoms in a patient diagnosed with amphetamine use disorder, including both pharmacological and non-pharmacological strategies?+
Managing amphetamine withdrawal requires a comprehensive approach addressing both the physical and psychological symptoms. Pharmacological interventions are currently limited and primarily focus on symptom management. While no FDA-approved medications specifically target amphetamine withdrawal, medications such as antidepressants and antipsychotics may be used to manage specific symptoms like depression, anxiety, and psychosis. Non-pharmacological strategies are central to long-term recovery. These include supportive care, ensuring adequate nutrition and hydration, and promoting sleep hygiene. Cognitive behavioral therapy (CBT) can assist patients in developing coping skills to manage cravings and triggers. Contingency management, offering positive reinforcement for abstinence, can improve treatment adherence. Explore how incorporating mindfulness-based interventions can complement CBT and support long-term recovery. Learn more about the stages of amphetamine withdrawal and tailoring interventions to each phase.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.